Related Experiment Video
Updated: Jun 1, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal
Robert S McKelvie1, Gordon W Moe, Anson Cheung
1Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada. robert.mckelvie@phri.ca
Insights
The 2011 Canadian Cardiovascular Society Heart Failure Guidelines update highlights new treatments like cardiac resynchronization therapy and aldosterone receptor antagonists for less symptomatic patients. It also stresses managing sleep apnea and advanced heart failure (HF) with palliative care and mechanical circulatory support (MCS).
Area of Science:
- Cardiology
- Pulmonology
- Geriatrics
Background:
- The 2011 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Focused Update addresses critical areas impacting patient management.
- Key topics include recent clinical trials, sleep apnea, and challenges in advanced HF.
Purpose of the Study:
- To review recent clinical trials relevant to HF management.
- To examine the role of sleep apnea in HF patients.
- To explore practical management strategies for advanced HF, including renal failure, palliative care, and mechanical circulatory support (MCS).
Main Methods:
- Review of recently published clinical trials.
- Assessment of clinical data on sleep apnea in HF.
- Examination of patient cases involving advanced HF, renal failure, palliative care, and MCS.
Main Results:
- Cardiac resynchronization therapy and aldosterone receptor antagonists show benefit in less symptomatic HF patients.
- Palliative care and addressing end-of-life issues are crucial in advanced HF.
- Sleep apnea is a significant complicating factor requiring assessment and management.
- MCS is indicated for acute severe or chronic advanced HF patients with good life expectancy or those awaiting transplantation.
Conclusions:
- Updated guidelines incorporate new evidence for HF treatment, including device and pharmacologic therapies.
- Comprehensive management of advanced HF requires attention to comorbidities like sleep apnea and renal failure, alongside palliative and supportive care.
- Referral for MCS is vital for select advanced HF patients to improve outcomes or bridge to transplantation.
Abstract:
The 2011 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Focused Update reviews the recently published clinical trials that will potentially impact on management. Also reviewed is the less studied but clinically important area of sleep apnea. Finally, patients with advanced HF represent a group of patients who pose major difficulties to clinicians. Advanced HF therefore is examined from the perspectives of HF complicated by renal failure, the role of palliative care, and the role of mechanical circulatory support (MCS). All of these topics are reviewed from a perspective of practical applications. Important new studies have demonstrated in less symptomatic HF patients that cardiac resynchronization therapy will be of benefit. As well, aldosterone receptor antagonists can be used with benefit in less symptomatic HF patients. The important role of palliative care and the need to address end-of-life issues in advanced HF are emphasized. Physicians need to be aware of the possibility of sleep apnea complicating the course of HF and the role of a sleep study for the proper assessment and management of the conditon. Patients with either acute severe or chronic advanced HF with otherwise good life expectancy should be referred to a cardiac centre capable of providing MCS. Furthermore, patients awaiting heart transplantation who deteriorate or are otherwise not likely to survive until a donor organ is found should be referred for MCS.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Cardiomyopathy V: Interprofessional Care
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy VI: Nursing Management
